| = 1 major infection (n = 23) | No major infection (n = 80) | p value |
---|---|---|---|
Laboratory variables | Â | Â | Â |
Functional MBL serum level, μg/mla | 1.60 (0.04–7.00) | 1.40 (0.04–7.60) | 0.316 |
Functional MBL serum level <0.05 μg/ml | 2/23 (9%) | 11/80 (14%) | 0.522 |
MBL-induced C4 deposition on mannan, percentagea | 64.8 (3.4–400) | 71.1 (1.1–400) | 0.550 |
MBL-induced C4 deposition on mannan <10% | 5/23 (22%) | 16/80 (20%) | 0.856 |
MBL pathway activity, percentagea | 14.1 (0.1–111) | 17.3 (0.1–119) | 0.806 |
MBL pathway activity <10% | 10/23 (44%) | 34/80 (43%) | 0.934 |
Clinical variables | Â | Â | Â |
Disease duration at follow-up, years | 12.5 ± 7.4 | 5.1 ± 5.7 | 0.0001 |
Previous SLE glomerulonephritis | 10/23 (44%) | 10/80 (10%) | 0.001 |
Treatment variables | Use <3 months before the first major infection | Previous use ever since lupus diagnosis | Â |
Oral corticosteroids | 17/23 (74%) | 41/80 (51%) | 0.916 |
Intravenous methylprednisolone | 5/23 (22%) | 9/80 (11%) | 0.204 |
Hydroxychloroquine | 6/23 (26%) | 70/80 (88%) | 0.0001 |
Methotrexate | 0/23 (0%) | 9/80 (11%) | 0.094 |
Azathioprine | 8/23 (35%) | 21/80 (26%) | 0.424 |
Oral cyclophosphamide | 1/23 (4%) | 1/80 (1%) | 0.373 |
Intravenous cyclophosphamide | 4/23 (17%) | 4/80 (5%) | 0.065 |